Published in Cell Tissue Bank on December 27, 2011
Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate (2013) 0.89
Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank. Biopreserv Biobank (2013) 0.76
Biobanking of Fresh-Frozen Human Adenocarcinomatous and Normal Colon Tissues: Which Parameters Influence RNA Quality? PLoS One (2016) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol (2013) 5.28
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Postoperative urinary retention: anesthetic and perioperative considerations. Anesthesiology (2009) 2.80
Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol (2005) 2.79
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. Eur Urol (2012) 2.36
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol (2009) 2.22
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst (2005) 2.04
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J (2007) 2.04
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol (2007) 2.02
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J (2009) 2.00
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
uPM3, a new molecular urine test for the detection of prostate cancer. Urology (2004) 1.91
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol (2004) 1.85
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther (2009) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol (2009) 1.70
Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int (2007) 1.68
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol (2012) 1.65
Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol (2003) 1.63
The aging male population and medical care for benign prostatic hyperplasia in Canada. Can Urol Assoc J (2010) 1.63
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol (2009) 1.59
Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology (2009) 1.58
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol (2006) 1.56
Length of prostate biopsy cores: does it impact cancer detection? Can J Urol (2013) 1.54
Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol (2007) 1.51
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J (2009) 1.51
Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer (2009) 1.51
Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol (2009) 1.49
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer (2008) 1.48
Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology (2010) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec. Can Urol Assoc J (2008) 1.45
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol (2007) 1.45
Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int (2010) 1.43
The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. Eur Urol (2011) 1.43
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol (2006) 1.42
Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res (2004) 1.40
Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. Can Urol Assoc J (2009) 1.38
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res (2006) 1.36
A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol (2009) 1.35
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. Radiology (2003) 1.33
Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int (2010) 1.31
Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res (2006) 1.30
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J (2012) 1.27
Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev (2011) 1.25
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. Can Urol Assoc J (2010) 1.21
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol (2008) 1.18
Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer (2008) 1.18